1793 related articles for article (PubMed ID: 8124687)
1. MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for interleukin-2 secretion and the expression of melanoma-associated antigens.
Kim TS; Cohen EP
Cancer Immunol Immunother; 1994 Mar; 38(3):185-93. PubMed ID: 8124687
[TBL] [Abstract][Full Text] [Related]
2. Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma.
Kim TS; Xu WS; Sun T; Cohen EP
Melanoma Res; 1995 Aug; 5(4):217-27. PubMed ID: 7496156
[TBL] [Abstract][Full Text] [Related]
3. Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of mice with melanoma.
Kim TS; Russell SJ; Collins MK; Cohen EP
Int J Cancer; 1993 Nov; 55(5):865-72. PubMed ID: 8244584
[TBL] [Abstract][Full Text] [Related]
4. Independent cell types are involved in the induction of antimelanoma responses in C57BL/6 mice immunized with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens.
Kim TS; Collins MK; Cohen EP
J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):298-304. PubMed ID: 7904182
[TBL] [Abstract][Full Text] [Related]
5. Immunization of mice with allogeneic fibroblasts genetically modified for interleukin-2-secretion and expression of melanoma-associated antigens stimulate predetermined classes of anti-melanoma effector cells.
Kim TS; Cohen EP
J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):24-35. PubMed ID: 8081557
[TBL] [Abstract][Full Text] [Related]
6. Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens.
Kim TS; Russell SJ; Collins MK; Cohen EP
Int J Cancer; 1992 May; 51(2):283-9. PubMed ID: 1533203
[TBL] [Abstract][Full Text] [Related]
7. H-2 antigen expression and sensitivity of BL6 melanoma cells to natural killer cell cytotoxicity.
Gorelik E; Gunji Y; Herberman RB
J Immunol; 1988 Mar; 140(6):2096-102. PubMed ID: 3126240
[TBL] [Abstract][Full Text] [Related]
8. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma.
Glick RP; Lichtor T; Mogharbel A; Taylor CA; Cohen EP
Neurosurgery; 1997 Oct; 41(4):898-906; discussion 906-7. PubMed ID: 9316052
[TBL] [Abstract][Full Text] [Related]
9. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.
Abdel-Wahab Z; Dar MM; Hester D; Vervaert C; Gangavalli R; Barber J; Darrow TL; Seigler HF
Cell Immunol; 1996 Aug; 171(2):246-54. PubMed ID: 8806794
[TBL] [Abstract][Full Text] [Related]
10. Resistance to melanoma in mice immunized with semiallogeneic fibroblasts transfected with DNA from mouse melanoma cells.
de Zoeten EF; Carr-Brendel V; Cohen EP
J Immunol; 1998 Mar; 160(6):2915-22. PubMed ID: 9510195
[TBL] [Abstract][Full Text] [Related]
11. Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2.
Glick RP; Lichtor T; de Zoeten E; Deshmukh P; Cohen EP
Neurosurgery; 1999 Oct; 45(4):867-74. PubMed ID: 10515482
[TBL] [Abstract][Full Text] [Related]
12. Decline in MHC class I expression with increasing thickness of cutaneous melanomas in standard-strain transgenic mouse models.
Milling SW; Silvers WK; Sai T; Mintz B
Melanoma Res; 2002 Jun; 12(3):221-30. PubMed ID: 12140378
[TBL] [Abstract][Full Text] [Related]
13. Immunity to melanoma in mice immunized with transfected allogeneic mouse fibroblasts expressing melanoma-associated antigens.
Kim YS; Slomski R; Cohen EP
Cancer Immunol Immunother; 1991; 34(3):163-8. PubMed ID: 1756533
[TBL] [Abstract][Full Text] [Related]
14. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
Chen PW; Ananthaswamy HN
J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
[TBL] [Abstract][Full Text] [Related]
15. Co-expression of immunogenic determinants by the same cellular immunogen is required for the optimum immunotherapeutic benefit in mice with melanoma.
Xu W; de Zoeten E; Carr-Brendel V; Cohen EP
Cancer Immunol Immunother; 1998 Jan; 45(5):217-24. PubMed ID: 9439644
[TBL] [Abstract][Full Text] [Related]
16. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action.
Mitchell MS; Harel W; Kan-Mitchell J; LeMay LG; Goedegebuure P; Huang XQ; Hofman F; Groshen S
Ann N Y Acad Sci; 1993 Aug; 690():153-66. PubMed ID: 8368734
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic activity toward mouse melanoma following immunization of mice with transfected cells expressing a human melanoma-associated antigen.
Nowak J; Cohen EP; Graf LH
Cancer Immunol Immunother; 1991; 33(2):91-6. PubMed ID: 1674672
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma.
Kim TS; Cohen EP
Cancer Res; 1994 May; 54(10):2531-5. PubMed ID: 8168073
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of therapeutic antitumor immunity by B16F10 melanoma cells transfected by interferon-gamma and allogeneic MHC class I cDNAs.
Lim YS; Kang BY; Kim EJ; Kim SH; Hwang SY; Kim TS
Mol Cells; 1998 Oct; 8(5):629-36. PubMed ID: 9856353
[TBL] [Abstract][Full Text] [Related]
20. Involvement of MHC class I molecule and ICAM-1 in the enhancement of adhesion and cytotoxic susceptibility to immune effector cells of tumor cells transfected with the interleukin (IL)-2, IL-4 or IL-6 gene.
Cao X; Chen G; He L; Zhang W; Yu Y; Wang J
J Cancer Res Clin Oncol; 1997; 123(11-12):602-8. PubMed ID: 9620217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
